Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Tilray Brands, Inc. TLRY

Alternate Symbol(s):  T.TLRY

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis business, Distribution business, Beverage alcohol business and Wellness business. The Cannabis business segment is engaged in the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. The Distribution business segment is focused on the purchase and resale of pharmaceutical products to customers. The Beverage alcohol business segment is engaged in the production, marketing and sale of beverage and beverage alcohol products. The Wellness business segment includes hemp foods and hemp-based cannabidiol (CBD) consumer products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Bake Sale, XMG, Mollo, and others.


NDAQ:TLRY - Post by User

Comment by okgonowon May 02, 2024 3:40pm
49 Views
Post# 36020196

RE:RE:RE:RE:We're prepared to export cannabis to the U.S. medical market

RE:RE:RE:RE:We're prepared to export cannabis to the U.S. medical marketI think there is alot of people out there that are being bamboozeled or are under-informed when it comes to what is actually happening in the US and for that matter in Germany. 

But lets just stick to US resceduling of Medical MJ as i said in m previous posts, for you to qualify as a medical MJ suplier you have to have FDA/DEA licence and your production facility has to have FDA aproval.

then if you are producing something that either gets used in a product sold all over the US or an actual product you have developed to be sold all over the US you also have to go the long process of clinical trials and submitting the eveidence to the FDA then to possibly get aproved by them for whatever ailment you say its for.

why is the fact that the US re-sceduole a great thing ...because the product you are now selling is not put in the same catagory( scedule1) as a product containing Heroin, cocaine, opium, oxycodone, fentanyl, morphine, methamphetamine, and amphetamines (the worst most adictive stuff in esscence)
there are some other advantages like you can write off costs in developing the new product and some other stuff but above is certainly the most important thing.

now unless all these MJ companys like Tillray/Canopy etc. plan on getting into the pharma market and get all the nesscary clearances and go thru the clinical trial stuff this in the short/medium tearm does nothing for any of them.

the only thing it may do for their customers is that they wont be charged federaly with possesion of a product on the same level as holding Cocaine or Heroine 

the advantage for the companys that do hold all the licences and can supply either a aproved FDA aproved API to be included in a drug , or those who have developed a drug with Medical canabis in it now have a drug/ product that is no longer regulated and put on the same level as Opiates and any of the highly regulated worst medications.
you are now on the shelf with Apirin and the like.

<< Previous
Bullboard Posts
Next >>